TTR
EstablishedTTR misfolding causes ATTR amyloidosis, an underdiagnosed cause of heart failure with a rapidly expanding treatment landscape.
TTR is a protein that can misfold and build up as a sticky substance in the heart and nerves as people age, causing a serious and long under-recognized disease. Treatment for this has exploded very recently: from just one approved drug through 2024, doctors now have several real options, including one approved as recently as November 2024.
Transthyretin (TTR) is a liver-produced protein that transports thyroid hormone and vitamin A in blood; historically used as a nutrition marker ("prealbumin"), it is now most clinically significant as the protein that misfolds to cause ATTR amyloidosis.
Misfolded TTR protein deposits as amyloid in the heart (causing cardiomyopathy) and peripheral nerves (causing neuropathy); ATTR amyloidosis exists in hereditary (from TTR gene mutations) and wild-type (age-related, mainly affecting men over 70) forms, and is increasingly recognized as an underdiagnosed cause of heart failure with preserved ejection fraction in older adults.
Diagnosis increasingly uses noninvasive radionuclide scintigraphy imaging in patients with a negative monoclonal protein screen, avoiding the need for a cardiac biopsy in many cases; clinical suspicion is often raised by heart failure combined with musculoskeletal clues like bilateral carpal tunnel syndrome or spinal stenosis.
Treatment has expanded dramatically and very recently: tafamidis was the only approved therapy from 2019-2024, but acoramidis (a more potent TTR stabilizer) gained FDA approval in November 2024, and gene-silencing drugs (vutrisiran, eplontersen) have also reached approval — clinicians now have multiple disease-modifying options where there were essentially none just a few years ago, per a 2025 ACC clinical guidance update.
Treatment options expanded dramatically in 2024-2025, with acoramidis, vutrisiran, and eplontersen joining tafamidis.
- JACC. (2025). Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.
- MDPI. (2025). Transthyretin Amyloid Cardiomyopathy—2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options.